{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:58:15Z","timestamp":1778561895957,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.canep.2019.101628","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:32:32Z","timestamp":1573259552000},"page":"101628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data"],"prefix":"10.1016","volume":"63","author":[{"given":"Matthew G.","family":"Parry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunan","family":"Sujenthiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Nossiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cathcart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel W.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Payne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.canep.2019.101628_bib0005","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate Cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2019.101628_bib0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","article-title":"The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone","volume":"21","author":"McDougall","year":"2016","journal-title":"Oncologist."},{"issue":"11","key":"10.1016\/j.canep.2019.101628_bib0015","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/cam4.914","article-title":"Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis","volume":"5","author":"Hussain","year":"2016","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.canep.2019.101628_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"1","key":"10.1016\/j.canep.2019.101628_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"Norgaard","year":"2010","journal-title":"J Urol."},{"key":"10.1016\/j.canep.2019.101628_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12874-015-0047-5","article-title":"Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods","volume":"15","author":"Aly","year":"2015","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"10.1016\/j.canep.2019.101628_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/pcan.2012.42","article-title":"Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases","volume":"16","author":"Hagiwara","year":"2013","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.canep.2019.101628_bib0040","series-title":"First Year Annual Report - Organisation of Services and Analysis of Existing Clinical Data","author":"National Prostate Cancer Audit","year":"2014"},{"key":"10.1016\/j.canep.2019.101628_bib0045","unstructured":"World Health Organisation. International Statistical Classification of Diseases and Related Health Problems (10th Revision). Available at: http:\/\/www.who.int\/classifications\/icd\/ICD10Volume2_en_2010.pdf (Accessed September 28, 2017)."},{"key":"10.1016\/j.canep.2019.101628_bib0050","series-title":"Third Year Annual Report - Results of the NPCA Prospective Audit and Patient Survey","author":"National Prostate Cancer Audit","year":"2016"},{"key":"10.1016\/j.canep.2019.101628_bib0055","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.canep.2019.101628_bib0060","unstructured":"National Health Service. Hospital Episode Statistics Available at: http:\/\/www.hesonline.nhs.uk (accessed January 15, 2017)."},{"key":"10.1016\/j.canep.2019.101628_bib0065","unstructured":"National Cancer Registration and Analysis Service. National Radiotherapy Dataset (RTDS) Available at: http:\/\/www.ncin.org.uk\/collecting_and_using_data\/rtds (Accessed December 11, 2017)."},{"key":"10.1016\/j.canep.2019.101628_bib0070","unstructured":"NHS Digital. NHS Classifications Service: OPCS Classifications of Interventions and Procedures Version 4.4; Available at: http:\/\/systems.digital.nhs.uk\/data\/clinicalcoding\/codingstandards\/opcs4 (Accessed 28 September, 2017)."},{"issue":"3","key":"10.1016\/j.canep.2019.101628_bib0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.urolonc.2013.09.004","article-title":"Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer","volume":"32","author":"Kowalczyk","year":"2014","journal-title":"Urol Oncol."},{"issue":"3","key":"10.1016\/j.canep.2019.101628_bib0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2019.101628_bib0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1536867X0400400201","article-title":"Cumulative incidence estimation in the presence of competing risks","volume":"4","author":"Coviello","year":"2004","journal-title":"Stata J."},{"issue":"2","key":"10.1016\/j.canep.2019.101628_bib0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate Cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol."},{"issue":"2","key":"10.1016\/j.canep.2019.101628_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol."},{"issue":"10024","key":"10.1016\/j.canep.2019.101628_bib0100","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.canep.2019.101628_bib0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl J Med."},{"issue":"33","key":"10.1016\/j.canep.2019.101628_bib0110","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.canep.2019.101628_bib0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/pubmed\/fdr054","article-title":"Systematic review of discharge coding accuracy","volume":"34","author":"Burns","year":"2012","journal-title":"J. Public Health Oxf. (Oxf)."},{"key":"10.1016\/j.canep.2019.101628_bib0120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canep.2018.11.003","article-title":"Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions","volume":"58","author":"Parry","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"5","key":"10.1016\/j.canep.2019.101628_bib0125","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.ijrobp.2017.08.018","article-title":"Hospital quality factors influencing the mobility of patients for radical prostate Cancer radiation therapy: a national population-based study","volume":"99","author":"Aggarwal","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.canep.2019.101628_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","article-title":"Metastatic prostate cancer remains incurable, why?","volume":"6","author":"Dong","year":"2019","journal-title":"Asian J Urol."},{"issue":"2","key":"10.1016\/j.canep.2019.101628_bib0135","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S1470-2045(18)30917-3","article-title":"Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective","volume":"20","author":"Lievens","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119301389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782119301389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:26:40Z","timestamp":1761802000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782119301389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"alternative-id":["S1877782119301389"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2019.101628","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2019.101628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101628"}}